Identification of a signature gene set for oxaliplatin sensitivity prediction in colorectal cancer
Our study identifies a novel four-gene signature that is strongly associated with oxaliplatin sensitivity in colorectal cancer. These findings support developing prognostic biomarkers to optimize oxaliplatin use, aiming to identify sensitive patients and avoid treatment for those with resistance.
Authors
- Daming Yang
- Zhaoxia Wu (ORCID: https://orcid.org/0000-0001-6230-7452)
- Haixia Peng (ORCID: https://orcid.org/0000-0002-2417-051X)
- Chang-Ping Hu
- Ying Xu (ORCID: https://orcid.org/0000-0001-9994-9889)
- Xinyue Li (ORCID: https://orcid.org/0000-0003-1972-9021)
- Ji Li (ORCID: https://orcid.org/0000-0002-0899-4412)
- Fengli Zhou
- Zhan Xiong (ORCID: https://orcid.org/0000-0001-7793-5662)
- Yimin Chu
Institutions
- Tongren Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-27
- DOI
- https://doi.org/10.3389/fonc.2025.1701328
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- Shanghai Jiao Tong University